Compare MRM & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRM | NCEL |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | Japan | Switzerland |
| Employees | N/A | 11 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 13.2M |
| IPO Year | 2020 | N/A |
| Metric | MRM | NCEL |
|---|---|---|
| Price | $1.35 | $2.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 169.3K | 27.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $1.89 |
| 52 Week High | $4.45 | $4.70 |
| Indicator | MRM | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 33.80 | 55.47 |
| Support Level | $1.21 | $2.44 |
| Resistance Level | $1.75 | $3.19 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 30.43 | 38.72 |
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.